Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

97.64 +0.50 (+0.51%)
Official Closing Price Updated: 7:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
42 43 Next >
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
Patients had big decreases in LDL cholesterol. But there were some side effects. 
Via Investor's Business Daily
How Is The Market Feeling About Novartis?
Via Benzinga
3 Spectacular High-Yield Dividend Stocks to Buy in November
Income investors should find plenty to like with these stocks. 
Via The Motley Fool
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novartis Hikes Its Earnings Outlook For The Third Time This Year
The company also beat third-quarter expectations after spinning off its Sandoz unit. 
Via Investor's Business Daily
Earnings Outlook For Novartis
Via Benzinga
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN).  IgAN is a major cause of... 
Via Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
The U.S. 
Via Benzinga
Exposures Product Safety
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
2 Green Flags and 1 Red Flag for Novartis Stock
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes. 
Via The Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations. 
Via InvestorPlace
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating. 
Via Investor's Business Daily
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline
According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,... 
Via SBWire
Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy
--News Direct-- 
Via News Direct
US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results
Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day losing streak in the previous session. The uptick in... 
Via Benzinga
Topics Bonds Stocks
Exposures Debt Markets US Equities
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Novartis AG (NYSE: NVS) reported  
Via Benzinga
Topics Earnings
Exposures Financial
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
2 Biotech Stocks That Could Make You Richer
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks. 
Via The Motley Fool
3 Unstoppable Stocks to Buy and Hold for Decades
These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification. 
Via The Motley Fool
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
Weight Loss Drugs Market Size, Share, Growth, Trends, Analysis 2028
Get an extensive Weight Loss Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Antiparasitic Drugs Market to See Major Growth by 2023-2030 : Arbor Pharmaceuticals, GlaxoSmithKline, Cipla
Get an extensive Antiparasitic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space. 
Via Benzinga
Cancer Immunotherapies Market Set for More Growth : American Cancer Society, WebMD, Eli Lily and Company
Get an extensive Cancer Immunotherapies Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
AbbVie Stock Moves Higher With Rising Relative Strength
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue? 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.